Naitee Ting
Research Subjects
Naitee Ting has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Shuyen Ho
Parexel International
9 shared publicationsDing-Geng Chen
University of North Carolina
8 shared publicationsJoseph C. Cappelleri
Pfizer, Inc
8 shared publicationsQiqi Deng
Biostatistics Moderna, Inc Cambridge MA USA
8 shared publications- Joseph Christopher Cappelleri
Pfizer Inc. New York New York USA
6 shared publications - Ding-Geng Chen
College of Health Solutions Arizona State University Phoenix Arizona USA
4 shared publications
Latest Publications
- Open Access
- 11 June 2025
- Published by Wiley in Statistics in Medicine
- Vol. 44 (13-14) , e70154
Consistency‐Based Approach to Adjust for Multiplicity in Confirmatory Subgroup Analysis
With the advance of medical sciences and better understanding of human biological systems, the next generation of treatment has shifted toward personalized medicine. It is expected that personalized medicine, such as molecularly targeted anti‐cancer agents, is more efficacious in marker‐positive patients, while marker‐negative patients may or may not benefit from the treatment. Due to technology limitations in marker identification and incomplete understanding of the role of biomarkers in treatment effect, it is possible that the marker is not predictive. Therefore, it is often of interest to test the treatment on the overall population as well as the biomarker‐positive subgroup. Testing both the overall population and the biomarker‐positive subgroup introduces a multiplicity issue and leads to type I error inflation if not adjusted appropriately. The available multiplicity adjustment procedures may not consider the logic needed in the two tests. A new method is proposed by applying the logical connections between the two hypothesis tests, and arbitrages between different rejection regions to make the testing strategy not only powerful but also sensible.
- 11 June 2025
- Published by Wiley in Statistics in Medicine
- Vol. 44 (13-14) , e70154
Open AccessConsistency‐Based Approach to Adjust for Multiplicity in Confirmatory Subgroup Analysis
With the advance of medical sciences and better understanding of human biological systems, the next generation of treatment has shifted toward personalized medicine. It is expected that personalized medicine, such as molecularly targeted anti‐cancer agents, is more efficacious in marker‐positive patients, while marker‐negative patients may or may not benefit from the treatment. Due to technology limitations in marker identification and incomplete understanding of the role of biomarkers in treatment effect, it is possible that the marker is not predictive. Therefore, it is often of interest to test the treatment on the overall population as well as the biomarker‐positive subgroup. Testing both the overall population and the biomarker‐positive subgroup introduces a multiplicity issue and leads to type I error inflation if not adjusted appropriately. The available multiplicity adjustment procedures may not consider the logic needed in the two tests. A new method is proposed by applying the logical connections between the two hypothesis tests, and arbitrages between different rejection regions to make the testing strategy not only powerful but also sensible.
- 29 October 2024
- Published by Springer Nature
- p. 201-218
Comparing MCP-Mod and Ordinal Linear Contrast Test in Dose-Finding Clinical Trials: A Thorough Examination
- 29 October 2024
- Published by Springer Nature
- p. 201-218
Comparing MCP-Mod and Ordinal Linear Contrast Test in Dose-Finding Clinical Trials: A Thorough Examination
- Open Access
- 15 April 2023
- Published by Taylor & Francis in Statistical Theory and Related Fields
- Vol. 7 (3) , 202-212
How to implement the ‘one patient, one vote’ principle under the framework of estimand
The scientific foundation of a modern clinical trial is randomization – each patient is randomized to a treatment group, and statistical comparisons are made between treatment groups. Because the study units are individual patients, this ‘one patient, one vote’ principle needs to be followed – both in study design and in data analysis. From the physicians' point of view, each patient is equally important, and they need to be treated equally in data analysis. It is critical that statistical analysis should respect design and study design is based on randomization. Hence from both statistical and medical points of view, data analysis needs to follow this ‘one patient, one vote’ principle. Under ICH E9 (R1), five strategies are recommended to establish ‘estimand’. This paper discusses how to implement these strategies using the ‘one patient, one vote’ principle.
- 15 April 2023
- Published by Taylor & Francis in Statistical Theory and Related Fields
- Vol. 7 (3) , 202-212
Open AccessHow to implement the ‘one patient, one vote’ principle under the framework of estimand
The scientific foundation of a modern clinical trial is randomization – each patient is randomized to a treatment group, and statistical comparisons are made between treatment groups. Because the study units are individual patients, this ‘one patient, one vote’ principle needs to be followed – both in study design and in data analysis. From the physicians' point of view, each patient is equally important, and they need to be treated equally in data analysis. It is critical that statistical analysis should respect design and study design is based on randomization. Hence from both statistical and medical points of view, data analysis needs to follow this ‘one patient, one vote’ principle. Under ICH E9 (R1), five strategies are recommended to establish ‘estimand’. This paper discusses how to implement these strategies using the ‘one patient, one vote’ principle.
- 8 April 2023
- Published by Springer Nature in Statistics in Biosciences
- Vol. 15 (2) , 1-15
Clinical Trial Design—What is the Critical Question for Decision-Making?
- 8 April 2023
- Published by Springer Nature in Statistics in Biosciences
- Vol. 15 (2) , 1-15
Clinical Trial Design—What is the Critical Question for Decision-Making?
- 22 March 2023
- Published by Oxford University Press (OUP) in Biometrics
- Vol. 79 (1) , 528-531
Confidence intervals for discrete data in clinical research By VivekPradhan, Ashis K.Gangopadhyay, Sandeep M.Menon, CynthiaBasu, TathagataBanerjee, Chapman and Hall. 2021. pp. 226. $119.95. (hbk). ISBN: 978‐1138048980
- 22 March 2023
- Published by Oxford University Press (OUP) in Biometrics
- Vol. 79 (1) , 528-531
Confidence intervals for discrete data in clinical research By VivekPradhan, Ashis K.Gangopadhyay, Sandeep M.Menon, CynthiaBasu, TathagataBanerjee, Chapman and Hall. 2021. pp. 226. $119.95. (hbk). ISBN: 978‐1138048980
- 27 February 2023
- Published by Taylor & Francis in Journal of Biopharmaceutical Statistics
- Vol. 33 (2) , 253-255
Emerging insights and commentaries – MMRM vs LOCF
ICH E9 (R1) lists five strategies to address estimand (ICH HARMONISED GUIDELINE 2017) – treatment policy, composite, hypothetical, principal stratum, and while on treatment strategies. Among these ...
- 27 February 2023
- Published by Taylor & Francis in Journal of Biopharmaceutical Statistics
- Vol. 33 (2) , 253-255
Emerging insights and commentaries – MMRM vs LOCF
ICH E9 (R1) lists five strategies to address estimand (ICH HARMONISED GUIDELINE 2017) – treatment policy, composite, hypothetical, principal stratum, and while on treatment strategies. Among these ...
- 8 December 2022
- Published by Taylor & Francis in Journal of Biopharmaceutical Statistics
- Vol. 33 (6) , 844-858
How to select the initial dose for a pediatric study?
- 8 December 2022
- Published by Taylor & Francis in Journal of Biopharmaceutical Statistics
- Vol. 33 (6) , 844-858
How to select the initial dose for a pediatric study?
- 2 October 2022
- Published by Taylor & Francis in Statistics in Biopharmaceutical Research
- Vol. 15 (4) , 748-754
Consistency Based Multiplicity Adjustment Approach—Multiple Doses in Phase III Studies
If two or more doses are employed in a Phase III clinical trial to compare to placebo, it is believed that the multiple doses can strengthen the understanding of a drug’s effect and increase the confidence in drug’s effect if consistent evidence is observed. In this article, a new approach is proposed to adjust for multiplicity introduced by multiple doses in phase III studies. Instead of dividing the significance level in the tests of individual doses, the new approach requires certain consistency to be demonstrated between the multiple active doses. The rejection regions of the new approach focus on the area of demonstrating consistent evidence, which is different from the rejection region of the Bonferroni correction. Detailed comparisons for the rejection regions between the Bonferroni and the new approach are provided. The comparisons explain how multiple doses can be used to strengthen the evidence without splitting the significance level. The rejection regions in the consistency-based method can help statisticians understand the role of multiplicity adjustment in study design and drug evaluation comprehensively.
- 2 October 2022
- Published by Taylor & Francis in Statistics in Biopharmaceutical Research
- Vol. 15 (4) , 748-754
Consistency Based Multiplicity Adjustment Approach—Multiple Doses in Phase III Studies
If two or more doses are employed in a Phase III clinical trial to compare to placebo, it is believed that the multiple doses can strengthen the understanding of a drug’s effect and increase the confidence in drug’s effect if consistent evidence is observed. In this article, a new approach is proposed to adjust for multiplicity introduced by multiple doses in phase III studies. Instead of dividing the significance level in the tests of individual doses, the new approach requires certain consistency to be demonstrated between the multiple active doses. The rejection regions of the new approach focus on the area of demonstrating consistent evidence, which is different from the rejection region of the Bonferroni correction. Detailed comparisons for the rejection regions between the Bonferroni and the new approach are provided. The comparisons explain how multiple doses can be used to strengthen the evidence without splitting the significance level. The rejection regions in the consistency-based method can help statisticians understand the role of multiplicity adjustment in study design and drug evaluation comprehensively.
- 1 November 2021
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 321 (5) , G500-G512
The potent and selective RIPK2 inhibitor BI 706039 improves intestinal inflammation in the TRUC mouse model of inflammatory bowel disease
Mouse and human data implicate the NOD1 and NOD2 sensors of the intestinal microbiome and the associated signal transduction via the receptor interacting protein kinase 2 (RIPK2) as a potential key signaling node for the development of inflammatory bowel disease (IBD) and an attractive target for pharmacological intervention. The TRUC mouse model of IBD was strongly indicated for evaluating RIPK2 antagonism for its effect on intestinal inflammation based on previous knockout studies with NOD1, NOD2, and RIPK2. We identified and profiled the BI 706039 molecule as a potent and specific functional inhibitor of both human and mouse RIPK2 and with favorable pharmacokinetic properties. We dosed BI 706039 in the spontaneous TRUC mouse model from age 28 to 56 days. Oral, daily administration of BI 706039 caused dose-responsive and significant improvement in colonic histopathological inflammation, colon weight, and terminal levels of protein-normalized fecal lipocalin (all P values <0.001). These observations correlated with dose responsively increasing systemic levels of the BI 706039 compound, splenic molecular target engagement of RIPK2, and modulation of inflammatory genes in the colon. This demonstrates that a relatively low oral dose of a potent and selective RIPK2 inhibitor can modulate signaling in the intestinal immune system and significantly improve disease associated intestinal inflammation. NEW & NOTEWORTHY The RIPK2 kinase at the apex of microbiome immunosensing is an attractive target for pharmacological intervention. A low oral dose of a RIPK2 inhibitor leads to significantly improved intestinal inflammation in the murine TRUC model of colitis. A selective and potent inhibitor of the RIPK2 kinase may represent a new class of therapeutics that target microbiome-driven signaling for the treatment of IBD.
- 1 November 2021
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 321 (5) , G500-G512
The potent and selective RIPK2 inhibitor BI 706039 improves intestinal inflammation in the TRUC mouse model of inflammatory bowel disease
Mouse and human data implicate the NOD1 and NOD2 sensors of the intestinal microbiome and the associated signal transduction via the receptor interacting protein kinase 2 (RIPK2) as a potential key signaling node for the development of inflammatory bowel disease (IBD) and an attractive target for pharmacological intervention. The TRUC mouse model of IBD was strongly indicated for evaluating RIPK2 antagonism for its effect on intestinal inflammation based on previous knockout studies with NOD1, NOD2, and RIPK2. We identified and profiled the BI 706039 molecule as a potent and specific functional inhibitor of both human and mouse RIPK2 and with favorable pharmacokinetic properties. We dosed BI 706039 in the spontaneous TRUC mouse model from age 28 to 56 days. Oral, daily administration of BI 706039 caused dose-responsive and significant improvement in colonic histopathological inflammation, colon weight, and terminal levels of protein-normalized fecal lipocalin (all P values <0.001). These observations correlated with dose responsively increasing systemic levels of the BI 706039 compound, splenic molecular target engagement of RIPK2, and modulation of inflammatory genes in the colon. This demonstrates that a relatively low oral dose of a potent and selective RIPK2 inhibitor can modulate signaling in the intestinal immune system and significantly improve disease associated intestinal inflammation. NEW & NOTEWORTHY The RIPK2 kinase at the apex of microbiome immunosensing is an attractive target for pharmacological intervention. A low oral dose of a RIPK2 inhibitor leads to significantly improved intestinal inflammation in the murine TRUC model of colitis. A selective and potent inhibitor of the RIPK2 kinase may represent a new class of therapeutics that target microbiome-driven signaling for the treatment of IBD.
- 15 October 2021
- Published by Springer Nature
- p. 121-129
Approaches to Combining Phase II Proof-of-Concept and Dose-Finding Trials
- 15 October 2021
- Published by Springer Nature
- p. 121-129
Approaches to Combining Phase II Proof-of-Concept and Dose-Finding Trials